Fiera Capital Corp Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Fiera Capital Corp cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 350,329 shares of the biotechnology company's stock after selling 9,667 shares during the period. Fiera Capital Corp owned about 0.37% of Sarepta Therapeutics worth $42,597,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in SRPT. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. increased its holdings in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares during the period. Huntington National Bank increased its holdings in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 175 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $36,000. Finally, Values First Advisors Inc. purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $59,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded down $1.51 on Friday, hitting $107.95. The company had a trading volume of 630,697 shares, compared to its average volume of 847,020. The firm has a market cap of $10.31 billion, a P/E ratio of 86.36 and a beta of 0.75. Sarepta Therapeutics, Inc. has a twelve month low of $102.15 and a twelve month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a 50-day moving average price of $119.42 and a 200-day moving average price of $124.72.

Analyst Ratings Changes

SRPT has been the topic of a number of analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a report on Monday, January 27th. Evercore ISI dropped their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. StockNews.com downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They set a "buy" rating and a $165.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Sarepta Therapeutics in a research note on Tuesday, February 11th. They set a "hold" rating and a $136.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $176.77.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.